Synthesis and in vitro activity of new methylenepiperidinyl and methylenepyrrolidinyl oxazolidinone antibacterial agents
摘要:
We have prepared and evaluated the antibacterial activities of a series of substituted methylenepiperidinyl and methyl-enepyrrolidinyl oxazolidinones against several gram-positive strains including the resistant strains of Staphyloccus and Enterococcus, such as MRSA, CRSA, MSSA and VRE. Some of them showed comparable or superior in vitro activities (MIC) to vancomycin. (C) 2003 Elsevier Science Ltd. All rights reserved.
The present invention provides agents having high antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel cyano-(substituted)-methylenepiperidinophenyl oxazolidinone derivatives, processes for making the compounds, as well as antimicrobial compositions containing said derivatives as active ingredients and methods of treating bacterial infections with the said derivatives.
Methylidene oxazolidinone compound and preparation method thereof
申请人:Korea Institute of Science and Technology
公开号:US20040087633A1
公开(公告)日:2004-05-06
A methylidene oxazolidinone compound represented by formula (1) or a pharmaceutically acceptable salt thereof, and a preparation method thereof, showing superior antimicrobial activities against gram-positive germs including resistant strains such as methicillic-resistant
staphylococcus aureus
and vancomycin-resistant enterococcus:
1
Synthesis and in vitro activity of new methylenepiperidinyl and methylenepyrrolidinyl oxazolidinone antibacterial agents
作者:Hye Yeon Kim、Jae Seok Lee、Joo Hwan Cha、Ae Nim Pae、Yong Seo Cho、Moon Ho Chang、Hun Yeong Koh
DOI:10.1016/s0960-894x(03)00249-x
日期:2003.7
We have prepared and evaluated the antibacterial activities of a series of substituted methylenepiperidinyl and methyl-enepyrrolidinyl oxazolidinones against several gram-positive strains including the resistant strains of Staphyloccus and Enterococcus, such as MRSA, CRSA, MSSA and VRE. Some of them showed comparable or superior in vitro activities (MIC) to vancomycin. (C) 2003 Elsevier Science Ltd. All rights reserved.